We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shake the fixe

13 May 2005 By Robert Cyran

Despite a 30% rise in the group s valuation since the merger, the market is still too sceptical on the French pharma group s prospects. The group deserves a premium due to its management and full pipeline. But the market is irrationally focussed on patent fears.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)